NCT07121387Completed
A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer
A Real-World Retrospective Cohort Analysis of SMARCA4-Deficient Advanced Lung Cancer
Source: ClinicalTrials.gov · Last updated 13 Aug 2025
Brief summary (registry, in English)
This is a single-center retrospective analysis to explore the clinical characteristics, therapeutic efficacy, and tumor immune microenvironment of SMARCA4-deficient advanced non-small-cell lung cancer (NSCLC).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 221 (actual)
- First submitted
- 6 Aug 2025
- Start date
- 1 Jan 2020
- Primary completion date
- 17 Dec 2024
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT07121387
What you commit to
- Study type: Observational
- Participants enrolled: 221
- From 1 Jan 2020 to the primary completion date, 17 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- SMARCA4 gene test was not performed;
- Not receive treatment;
- Lost to follow-up after one treatment cycle.
Who the study is looking for
- Diagnosed with stage III-IV NSCLC according to the American Joint Committee on Cancer staging criteria (7th edition);
- Lesions are measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;
- Receiving first-line immunotherapy or chemotherapy as anti-tumor treatment.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Pulmonary Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.